Abstract
The macrolide antibiotics, erythromycin and azithromycin, have been studied for their potential antimalarial activity, but only modest activity has been demonstrated. In this study, we investigated the enhancement of the efficacy of these antibiotics in combination with a patented lipid-based drug delivery system, Pheroid technology. A chloroquine resistant strain of Plasmodium falciparum (RSA11) was incubated with the formulations for a prolonged incubation time (144 h). Drug efficacy assays were conducted by analyzing the histidine-rich protein II levels of the parasites. The effects of azithromycin and erythromycin were compared with other antibiotics and standard antimalarial drugs. The poor water soluble nature of the drugs led to the formation of micro scale Pheroid vesicles with average particle sizes of 72.76±10.73 μm for azithromycin and 100.62±29.27 μm for erythromycin. The IC50 values of erythromycin and azithromycin alone and entrapped in Pheroid vesicles decreased statistically significant (P⩽0.05). Prolonged exposure was also statistically meaningful (P⩽0.05), although it seems that exposure need not exceed 96 h. Pheroid vesicles also proved successful in decreasing the IC50 values of doxycycline, tetracycline and triclosan. Pheroid vesicles containing antibiotics could prove successful as a malaria treatment option.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
WHO.. World Malaria Report 2011, WHO: Geneva, Switzerland, (2011).
Cox, F. E. G. Modern Parasitology, A textbook of Parasitology 14–18 Blackwell Science: Cambridge, (1996).
Agnandji, S. T. First results of Phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863–1875 (2011).
O’Brien, C., Henrich, P. P., Passi, N. & Fidock, D. A. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr. Opin. Infect. Dis. 24, 570–577 (2011).
Pešić, D. et al. Design, synthesis, and in vitro activity of novel 2’-O-substituted 15-membered azalides. J. Med. Chem. 55, 3216–3227 (2012).
Perić, M. et al. Antimalarial activity of 9A-N- substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. J. Med. Chem. 55, 1389–1401 (2012).
Praveen Kumar, S. et al. Design, synthesis and evaluation of 3-methylene-substituted indolinones as antimalarials. Eur. J. Med. Chem. 46, 927–983 (2011).
Glória, P. M. C. et al. Aza vinyl sulfones: Synthesis and evaluation as antiplasmodial agents. Biorganic Med. Chem. 19, 7635–7642 (2011).
Banerjee, A. K., Arora, N. & Murty, U. S. N. Analysing a potential drug target N-myristoyltransferase of Plasmodium falciparum trough in silico approaches. J. Glob. Infect. Dis. 4, 43–54 (2012).
Qidwai, T. & Khan, F. Antimalarial drugs and drug targets specific to fatty acid metabolic pathway of Plasmodium falciparum. Chem. Biol. Drug. Des 80, 155–172 (2012).
Kuntworbe, N. & Al-Kassas, R. Design and in vitro haemolytic evaluation of cryptolepine hydrochloride-loaded gelatin nanoparticles as a novel approach for the treatment of malaria. AAPS Pharm. Sci. Tech. 13, 568–581 (2012).
Slabbert, C., du Plessis, L. H. & Kotzé, A. F. Evaluation of the physical properties and stability of two lipid drug delivery systems containing mefloquine. Int. J. Pharm. 409, 209–215 (2011).
Isacchi, B. et al. Artemisinin and artemisinin plus curcumin liposomal formulations: Enhanced antimalarial efficacy against Plasmodium berghei-infected mice. Eur. J. Pharm. Biopharm. 80, 528–534 (2012).
Nakornchai, S. & Konthiang, P. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium Falciparum in vitro. Acta Trop. 100, 185–191 (2006).
Pradines, B. et al. Antibiotics for prophylaxis of Plasmodium falciparum infections: in vitro activity against doxycycline against Senegalese insolates. Am. J. Trop. Med. Hyg. 62, 82–85 (2000).
Pradines, B. et al. In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron. Antimicrob. Agents Chemother. 45, 1746–1750 (2001).
Sood, S. K. Macrolides: clarithromycin and azithromycin. Semin. Pediatric Infect. Diseases 10, 23–30 (1999).
Chambers, H. F. in Basic and Clinical Pharmacology 9th edn. (Katzung B. G., ) 754–763 McGraw-Hill: New York, (2004).
Noedl, H. et al. Antimalarial activity of azithromycin, artemisinin and dihydroartemisinin in fresh isolates of Plamsodium falciparum in Thailand. Acta Trop. 80, 39–44 (2001).
Gingras, B. A. & Jensen, J. B. Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 47, 378–382 (1992).
Gingras, B. A. & Jensen, J. B. Antimalarial activity of azithromycin and erythromycin against Plasmodium berghei. Am. J. Trop. Med. Hyg. 49, 101–105 (1993).
Menezes, C. M. S. et al. In vitro evaluation of erythromycin in chloroquine-resistant brazilian P. falciparum freshly isolates: modulating effect and antimalarial activity evidence. Rev. I Med. Trop. 41, 249–253 (1999).
Pang, L. W. et al. Failure of large-dose erythromycin in combination with a standard dose of chloroquine or quinine in the treatment of human falciparum malaria. B. World Health Organ. 63, 739–743 (1985).
Sidhu, A. B. S. et al. In vitro efficacy, resistance selection, and structural modelling studies implicate the malarial parasite apicoplast as the target of azithromycin. J. Biol. Chem. 282, 2494–2504 (2006).
Miller, R. S. et al. Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study. Am. Soc. Trop. Med. Hyg. 74, 401–406 (2006).
Yeo, A. E. & Rieckman, K. H. Prolonged exposure of Plasmodium falciparum to ciprofloxacin increases anti-malarial activity. J. Parasitol. 80, 158–160 (1994).
Vallely, A., Vallely, L., Changalucha, J., Greenwood, B. & Chandramohan, D. Intermittent preventive treatment for malaria in pregnancy in Africa: what’s new, what’s needed? Malaria J. 6, 1–13 (2007).
Ohrt, C., Willingmyre, G. D., Lee, P., Knirsch, C. & Milhous, W. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 46, 2518–2524 (2002).
Anderson, S. L. et al. Efficacy of azithromycin as a causal prophylactic agent against murine malaria. Antimicrob. Agents Chemother. 38, 1862–1863 (1994).
Taylor, W. R. et al. Tolerability of azithromycin as malaria prophylaxis in adults in North East Papua, Indonesia. Antimicrob. Agents Chemother. 47, 2199–2203 (2003).
Andersen, S. L. et al. Successful doubleblinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin. Infect. Dis. 26, 146–150 (1998).
Krudsood, S. et al. A randomised clinical trial of combination artesunate and azithromycin for treatment of uncomplicated Plasmodium falciparum malaria in Thailand. Southeast Asian J. Trop. Med. Public Health. 31, 801–807 (2000).
Chico, R. M., Pittrof, R., Greenwood, B. & Chandramohan, D. Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malaria J. 7, 255–269 (2008).
Du Plessis, L. H., Lubbe, J., Strauss, T. & Kotzé., A. F. Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid™ fatty acid based delivery system, and by N-trimethyl chitosan chloride. Int. J. Pharm. 385, 181–186 (2010).
Steyn, J. D. et al. Absorption of the novel artemisinin derivatives artemisone and artemiside: Potential application of Pheroid™ technology. Int. J. Pharm. 414, 260–266 (2011).
Thipine, M., Letscher-Bru, V. & Herbrecht, R. Amphoterecin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl. Infect. Dis. 1999, 273–283 (1999).
Oh, Y.-K., Nix, D. E. & Straubinger, R. M. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimcrob. Agents Chemother. 39, 2104–2111 (1995).
Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. Science 193, 673–675 (1976).
Chingunpituk, J. Nanosuspension technology for drug delivery. Walailak J. Sci. Tech. 4, 139–153.
Stepniewska, K., Chotivanich, K., Brockman, A., Day, N. P. J. & White, N. J. Overestimating resistance in field testing of malaria parasites: simple methods for estimating high EC50 values using a Bayesian approach. Malaria J. 6, 4–13 (2007).
Lo, J. B., Appel, L. E., Herbig, S. M., McCray, S. B. & Thombre, A. G. Formulation design and pharmaceutical development of a novel controlled release form of azithromycin for single-dose therapy. Drug. Dev. Indus. Pharm. 35, 1522–1529 (2009).
Kifude, C. M. et al. Enzyme-linked immunosorbent assay for detection of Plasmodium falciparum histidine-rich protein 2 in blood, plasma and serum. Am. Soc. Microbiol. 15, 1012–1018 (2008).
Noedl, H., Wongsrichanalai, C. & Wernsdorfer, W. H. Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol. 19, 175–181 (2003).
Dahl, E. L. & Rosenthal, P. J. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob. Agents Chemother. 51, 3485–3490 (2007).
Fivelman, Q. L., Walden, J. C., Smith, P. J., Folb, P. I. & Barnes, K. I. The effect of artesunate combined with standard chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Trans. 93, 429–432 (1999).
Wu, C.-P., Van Schalwyk, D. A., Taylor, D., Smith, P. J. & Chibale, K. Reversal of chloroquine resistance in Plasmodium falciparum by 9H-xanthine derivatives. Int. J. Antimicrob. Agents 26, 170–175 (2005).
Achan, J. et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malaria J. 10, 144 (2011).
Agwuh, K. N. & MacGowan, A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J. Antimcrob. Chemother. 58, 256–265 (2006).
Delves, M. et al. The activities of current antimalarial drugs on the life cycles of Plasmodium: A comparative study with human and rodent parasites. PLOS Med. 9, e1001169 (2012).
Surolia, N. & Surolia, A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nature Med. 7, 167–173 (2001).
Kuo, M. R. Targeting tuberculosis and malaria through inhibition of enoyl reductase. J. Biol. Chem. 23, 20851–20859 (2003).
Waller, R. F. et al. Nuclera-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc. Natl Acad. Sci. USA 95, 12352–12357 (1998).
Baschong, W. et al. Triclosan is minimally effective in rodent malaria models. Nature Med. 17, 33–34 (2011).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Du Plessis, L., van Niekerk, A., Maritz, M. et al. In vitro activity of Pheroid vesicles containing antibiotics against Plasmodium falciparum. J Antibiot 65, 609–614 (2012). https://doi.org/10.1038/ja.2012.89
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2012.89
